• A retrospective chart review was conducted to determine the prognostic effect of estrogen receptor (ER) protein in patients with node-negative operable breast cancer. One hundred nine patients with breast cancer whose tumors underwent ER analysis and whose lymph node negativity was established histologically were studied. Based on life-table analysis, the overall survival at six years was 92.7% for ER-positive patients, 95.3% for ER-negative patients, and 94.4% for ER-borderline patients. The disease-free survival was 83.3%, 92.8%, and 71.4%, respectively. Survival and diseasefree survival were also correlated to menopausal status. The difference in survival was not statistically significant at six years. We conclude that in node-negative primary operable breast cancer, ER status should not be used as a discriminant for adjuvant treatment.
(Arch Surg 1989;124:377-380)
Maki HS, Hoehn JL. Influence of Estrogen Receptors on Survival and Recurrence in Patients With Breast Cancer Without Lymph Node Metastases. Arch Surg. 1989;124(3):377-380. doi:10.1001/archsurg.1989.01410030127021